Protagonist Therapeutics (NASDAQ:PTGX) Cut to Hold at Zacks Research

Zacks Research cut shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a strong-buy rating to a hold rating in a research note released on Thursday,Zacks reports.

Several other equities analysts also recently issued reports on the company. Citigroup lifted their price objective on Protagonist Therapeutics from $175.00 to $182.00 and gave the company a “buy” rating in a research report on Monday, August 31st. The Goldman Sachs Group upgraded Protagonist Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $110.00 to $186.00 in a report on Monday, August 10th. Truist Financial raised their price objective on shares of Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Wolfe Research reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, August 31st. Finally, UBS Group restated a “buy” rating on shares of Protagonist Therapeutics in a research report on Tuesday, November 3rd. Sixteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $166.67.

Get Our Latest Research Report on Protagonist Therapeutics

Protagonist Therapeutics Trading Down 2.1%

Shares of Protagonist Therapeutics stock opened at $121.40 on Thursday. The stock has a market capitalization of $7.92 billion, a price-to-earnings ratio of 25.72 and a beta of 1.21. Protagonist Therapeutics has a 1-year low of $77.00 and a 1-year high of $160.81. The firm’s 50-day moving average price is $138.14 and its two-hundred day moving average price is $120.16.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $3.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. The company had revenue of $274.41 million during the quarter, compared to analysts’ expectations of $238.49 million. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. As a group, equities research analysts predict that Protagonist Therapeutics will post 5.52 EPS for the current year.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Molina sold 2,718 shares of the company’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $124.65, for a total value of $338,798.70. Following the completion of the sale, the insider owned 81,397 shares of the company’s stock, valued at approximately $10,146,136.05. This represents a 3.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Asif Ali sold 58,629 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the completion of the sale, the chief financial officer owned 59,003 shares in the company, valued at approximately $8,365,445.34. This trade represents a 49.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 186,347 shares of company stock worth $26,891,786. 5.19% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

Large investors have recently modified their holdings of the business. Allworth Financial LP lifted its holdings in shares of Protagonist Therapeutics by 38.2% during the 3rd quarter. Allworth Financial LP now owns 351 shares of the company’s stock valued at $49,000 after purchasing an additional 97 shares in the last quarter. Global Retirement Partners LLC increased its stake in Protagonist Therapeutics by 9.8% during the 3rd quarter. Global Retirement Partners LLC now owns 1,158 shares of the company’s stock worth $163,000 after purchasing an additional 103 shares in the last quarter. TFB Advisors LLC raised its holdings in Protagonist Therapeutics by 3.0% during the 3rd quarter. TFB Advisors LLC now owns 5,394 shares of the company’s stock worth $760,000 after buying an additional 159 shares during the period. GAMMA Investing LLC raised its holdings in Protagonist Therapeutics by 7.2% during the 2nd quarter. GAMMA Investing LLC now owns 3,109 shares of the company’s stock worth $381,000 after buying an additional 208 shares during the period. Finally, Choreo LLC raised its holdings in Protagonist Therapeutics by 9.3% during the 3rd quarter. Choreo LLC now owns 2,533 shares of the company’s stock worth $357,000 after buying an additional 216 shares during the period. 98.63% of the stock is currently owned by institutional investors.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Featured Articles

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.